Ipamorelin Lab Studies and Research/Conclusions

Ipamorelin Lab Studies and Research/Conclusions

Ipamorelin Lab Studies

Ipamorelin is a peptide that has gained huge popularity because of its various benefits. Researchers are looking for ways to manipulate to bring about the postulated benefits. The peptide is composed of five amino acids in its chain mainly Aib-His-D-2-Nal-D-Phe-Lys-NH2 and it has a molecular mass of 711 Daltons. Research has shown that the peptide is classified as a GHS or growth hormone releasing secretagogue. Growth hormone releasing secretagogues are a group of peptides that are known to accentuate the release of growth hormone from the somatotrophs located on the pituitary gland. One of the main objectives of ipamorelin is to increase the somatic production of GH. The peptide was created after other predecessors in the category, which include GHRP-6 and GHRP-2, and is one of the cleanest and most effective peptide.

The secretion of growth hormone occurs in the pituitary gland and the peptide has gained huge interest from the medical and pharmaceutical industries for potential use. The mode of action of the peptide on the somatotrophs is still under research. However, preliminary studies indicated that the peptide has a positive feedback mechanism in increasing the amount of growth hormone produced per cell. The peptide is one of the growth hormone injections that are sold in the market for research. Studies have shown that the peptide is effective in increasing the production of growth hormone per cell. This is important because growth hormone plays a significant role in cell division, cell growth, development and maturity. The peptide is the third generation of the growth hormone secretagogues and the mechanism of action and the properties are similar to that of growth hormone releasing peptide 2. However, the growth hormone injections do not have lipogenic properties or induce hunger.

How Ipamorelin Works

How Ipamorelin Works
How Ipamorelin Works

The mechanism of action of ipamorelin is via the increment of the volume and number of growth hormone produce by the somatotrophic cells. Growth hormone releasing peptide 6 has similar characteristics as ipamorelin because it also increases the amount of ipamorelin produced per cell as well as the intensity. Research shows that GHRP-6 and GHRP-2 are known to promote the increase in cortisol and prolactin levels in the plasma and hexarelin is deemed to have the same characteristics as ipamorelin because it is one of the most stable forms of ghrelin. Moreover, ipamorelin has an extended half-life and it does not have any significant effect on the levels of insulin growth factor 1. However, it increases the levels of acetylcholine in the system. Acetylcholine is one of essential components in signal transduction because it initiates cell-to-cell communication and this promotes the binding of the growth hormone to the ligand.

Ipamorelin and Bone Growth

Ipamorelin and Bone Growth
Ipamorelin and Bone Growth

Ipamorelin is the latest analog of the naturally produced growth hormone. The synthetic peptide has distinct growth hormone releasing properties. According to research, the peptide has the ability to cause longitudinal bone growth as per research conducted on mice. During the research, the mice were injected with a dosage of the peptide, intravital tetracycline has used a probe to determine the distance between the bands on the proximal tibia metaphysis. After the study, scientists concluded that the  human growth hormone injections peptide has the ability to accentuate the release of growth hormone from the anterior lobe of the pituitary gland. When the growth hormone is released, it increases osteoclasts and this is important in the lengthening of the bone. It is important to note that the administration of ipamorelin did not affect the level of insulin growth factor biopeptides, insulin-like growth factor 1 and serum markers used in bone formation and resorption.

However, it should be noted that the number of tartarate acids resistant acid phosphatase positive multinuclear cells in the metaphysic of the tibia was not affected after the treatment. The response of the pituitary gland increased once the peptide was administered. Studies have shows that the main activity of the peptide is through the activation of the G-coupled protein. The G-coupled protein is an essential mechanism in the biological system because it increases gastric motility and gastric emptying. The target of the hormone is in the anterior lobe of the pituitary gland. However, human growth hormone side effects include no activity on the levels of luteinizing hormone, follicle-stimulating hormone TSH and PRL. A growth hormone releasing hormone receptor called GRLN is essential in activating tiny compounds on the pituitary gland and this induces the release of growth hormone. Ipamorelin acts on the same receptor to release growth hormone which is important in cell division, cell proliferation, differentiation and maturity.

Ipamorelin and Connective Tissues

Ipamorelin and Connective Tissues
Ipamorelin and Connective Tissues

According to recent studies, ipamorelin has a positive impact on sleep. When research mice were administered with the peptide, it contributes to a restorative sleep as it interferes with the rapid eye movement phase of sleep. The peptide increased sleep in mice and prolonged the third phase of sleep. However, the findings of the research are not comprehensive yet. Increased production and regeneration of the connective tissue is one of the main benefits of ipamorelin. It is found in large amounts in the connective tissues. The connective tissues play an important role in recovery, especially from cartilaginous injury and it also helps reduce wear and tear caused by intense training. Although ipamorelin can accentuate hypertrophy, the overall effect is not yet known and the bolstered immune system can be attributed to the high levels of the peptide in the system.

Growth hormone is released in a pulsatile manner from the somatotrophs of the pituitary gland and suppressing the effect of somatostatin is key in the production of an adequate amount of growth hormone. The growth hormone side effects include suppression of the antagonist somatostatin since they are both produced on the somatotroph cells. De novo applications indicate that it gradually initiates the release of human growth hormone in a natural and pulsating manner. There is a high possibility of using the hormone in practical diagnostics and therapeutic manner.

Growth hormone releasing peptide analogs are unnatural forms of D-amino acids which are developed for the growth hormone-releasing activity of the secretagogues. Though they lack opioid activity, they can be potent stimulators of growth hormone release.